Taiho gets option to Arcus' candidates

Cancer company Arcus Biosciences (Hayward, Calif.) granted Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) an option to develop and commercialize compounds in Japan and other Asian territories excluding China. Arcus said the deal includes anything listed on its pipeline chart.

Arcus will receive $35 million over the first three years of the five-year agreement and is eligible to receive up to $275 million in milestones for each molecule, plus high-single to mid-double-digit royalties. Arcus declined to disclose additional financial terms...